Name | 3-aminobicyclo[2.2.1]heptane-3-carboxylic acid |
---|---|
Synonyms |
2-aminonorbornane-2-carboxylic acid
MFCD00167580 b-BCH 2-AMINO-2-NORBORNANE-CARBOXYLIC ACID |
Description | LAT1-IN-1 (BCH) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis[1][2][3]. |
---|---|
Related Catalog | |
Target |
LAT1[1] |
In Vitro | LAT1-IN-1 (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner[1]. LAT1-IN-1 (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that LAT1-IN-1 induces cell cycle arrest at G1 phase[1]. LAT1-IN-1 (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased[1]. Cell Proliferation Assay[1] Cell Line: KYSE30 and KYSE150 esophageal cancer cells Concentration: 1 mM, 3 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, or 100 mM Incubation Time: 3 days Result: Cell proliferation was suppressed in a dose-dependent manner. Cell Cycle Analysis[1] Cell Line: KYSE30 and KYSE150 cells Concentration: 30 mM Incubation Time: 24 and 48 hours Result: Cell cycle arrest. Western Blot Analysis[1] Cell Line: KYSE30 and KYSE150 cells Concentration: 30 mM Incubation Time: 0 hour, 0.5 hour, 1 hour, 3 hours, 6 hours, 24 hours Result: Phosphorylation of 4E-BP1 and p70S6K was decreased. The amount of mTOR, 4E-BP1, and p70S6K proteins was slightly decreased. |
In Vivo | LAT1-IN-1 (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo[1]. Animal Model: Male BALB/c nude mice (5-week-old) with KYSE150 cells[1] Dosage: 200 mg/kg Administration: Intravenous injection; daily; for 14 days Result: Significantly delayed tumor growth and decreased glucose metabolism. |
References |
Density | 1.256g/cm3 |
---|---|
Boiling Point | 295.5ºC at 760 mmHg |
Melting Point | >300 °C(lit.) |
Molecular Formula | C8H13NO2 |
Molecular Weight | 155.19400 |
Flash Point | 132.5ºC |
Exact Mass | 155.09500 |
PSA | 63.32000 |
LogP | 1.28880 |
Vapour Pressure | 0.000369mmHg at 25°C |
Index of Refraction | 1.559 |
RIDADR | NONH for all modes of transport |
---|---|
WGK Germany | 3 |
HS Code | 2922499990 |
~% 20448-79-7 |
Literature: Tetrahedron Letters, , vol. 21, p. 4101 - 4104 |
Precursor 1 | |
---|---|
DownStream 0 |
HS Code | 2922499990 |
---|---|
Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |